Aug. 15 at 2:48 PM
$DARE Reading through the 10K, there's a lot of bleh news:
- Ovaprene only has 115 recruits out of 250. They stopped recruitment because they were afraid of losing funding from the NIH cuts. They got a grant to do more but are unsure what to do. No definite timeline, definitely not done in 2025.
- Sildenafil still looking for FDA updates. FDA gutted by admin cuts, long turnaround time. Definitely not starting Ph3 in 2025.
- They diluted up to 13.5 million shares, 5 million more than now. It'll give them cash for the next year, but they're not getting any FDA approvals til late 2026.
- Just really disappointing delays all around. A lot out of their control, but we've been waiting for so long now.
- My guess is we go a fair bit lower and eventually get a pump. Maybe more grant money, maybe partnership deal(s).
- This company has a lot of potential, but there is a ton of risk. And the timelines for genuine positives is uncertain. Plan accordingly.
